@article{79ad8ec1cb594960b833b32f88242109,
title = "Estimating the risk of thrombotic events in people with congenital hemophilia A using US claims data",
abstract = "Aim: Compare thrombotic risk in people with congenital hemophilia A (PwcHA) to the general non-hemophilia A (HA) population. Patients & methods: US claims databases were analyzed to identify PwcHA. Incidence rates of myocardial infarction, pulmonary embolism, ischemic stroke, deep vein thrombosis and device-related thrombosis were compared with a matched cohort without HA. Results: Over 3490 PwcHA were identified and 16,380 individuals matched. PwcHA had a similar incidence of myocardial infarction and pulmonary embolism compared with the non-HA population, but a slightly higher incidence of ischemic stroke and deep vein thrombosis. The incidence of device-related thrombosis was significantly higher in PwcHA. Conclusion: This analysis suggests that PwcHA are not protected against thrombosis, and provides context to evaluate thrombotic risk of HA treatments.Tweetable abstract People with #hemophilia A are not protected against thrombotic events and should be monitored for thrombotic risk factors; the thrombotic risk of hemophilia A treatments should also be evaluated.",
keywords = "hemophilia A, hemostasis, ischemic stroke, myocardial infarction, pulmonary embolism, therapeutics, thrombosis, vascular access devices, venous thrombosis, VENOUS ACCESS DEVICES, FACTOR-VIII, CARDIOVASCULAR-DISEASE, EMICIZUMAB, PROPHYLAXIS",
author = "I. Faghmous and F. Nissen and P. Kuebler and C. Flores and A.M. Patel and S.W. Pipe",
note = "Funding Information: This work was supported by F. Hoffmann-La Roche Ltd. None of the authors received honoraria or fees for their contribution to the development of this manuscript. I Faghmous is a previous employee of F. Hoffmann-La Roche Ltd and Gilead Sciences, Inc. F Nissen is a current employee of F. Hoffmann-La Roche Ltd. P Kuebler is a current employee of and holds shares in Genentech, Inc. C Flores is a current employee of Genesis Research. AM Patel is a current employee of Genentech, Inc. SW Pipe has received consultancy and honoraria from Apcintex Ltd., Bayer AG, BioMarin Pharmaceutical, Catalyst Biosciences, CSL Behring, HEMA Biologics Inc., F. Hoffmann-La Roche Ltd., Freeline Therapeutics, Novo Nordisk, Pfizer Inc., Sangamo Therapeutics Inc., Sanofi, Takeda Pharmaceutical Company Ltd., Spark Therapeutics Inc. and uniQure NV; has received research funding from Siemens AG; and is a member of the board of directors/advisory committee for the Medical and Scientific Advisory Council to the National Hemophilia Foundation and the Medical Advisory Board to World Federation of Hemophilia. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Publisher Copyright: {\textcopyright} 2021 F. Hoffmann-La Roche Ltd.",
year = "2021",
month = oct,
doi = "10.2217/cer-2021-0120",
language = "English",
volume = "10",
pages = "1323--1336",
journal = "Journal of Comparative Effectiveness Research",
issn = "2042-6305",
publisher = "Future Medicine Ltd.",
number = "18",
}